These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30705268)

  • 1. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
    Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
    Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for
    Gao Y; Hameed HMA; Liu Y; Guo L; Fang C; Tian X; Liu Z; Wang S; Lu Z; Islam MM; Zhang T
    Acta Pharm Sin B; 2021 Mar; 11(3):738-749. PubMed ID: 33777679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL
    PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buruli ulcer and mycolactone-producing mycobacteria.
    Nakanaga K; Yotsu RR; Hoshino Y; Suzuki K; Makino M; Ishii N
    Jpn J Infect Dis; 2013; 66(2):83-8. PubMed ID: 23514902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A New Mycobacterium ulcerans Genotype Causing Buruli Ulcer in Côte d'Ivoire.
    Bahadoran P; Hammoudi N; Gaudart A; Saad J; Di Filippo Y; Drancourt M; Ruimy R
    Am J Trop Med Hyg; 2021 Apr; 104(5):1782-1783. PubMed ID: 33819173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnopharmacological reports on anti-Buruli ulcer medicinal plants in three West African countries.
    Tsouh Fokou PV; Nyarko AK; Appiah-Opong R; Tchokouaha Yamthe LR; Addo P; Asante IK; Boyom FF
    J Ethnopharmacol; 2015 Aug; 172():297-311. PubMed ID: 26099634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic management of
    Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.
    Tobias NJ; Seemann T; Pidot SJ; Porter JL; Marsollier L; Marion E; Letournel F; Zakir T; Azuolas J; Wallace JR; Hong H; Davies JK; Howden BP; Johnson PD; Jenkin GA; Stinear TP
    PLoS Negl Trop Dis; 2009 Nov; 3(11):e553. PubMed ID: 19936295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.
    Demangel C; Stinear TP; Cole ST
    Nat Rev Microbiol; 2009 Jan; 7(1):50-60. PubMed ID: 19079352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer.
    Doig KD; Holt KE; Fyfe JA; Lavender CJ; Eddyani M; Portaels F; Yeboah-Manu D; Pluschke G; Seemann T; Stinear TP
    BMC Genomics; 2012 Jun; 13():258. PubMed ID: 22712622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Informatics Studies of the Iron-Dependent Regulator (ideR) Reveal Potential Novel Anti-
    Kwofie SK; Enninful KS; Yussif JA; Asante LA; Adjei M; Kan-Dapaah K; Tiburu EK; Mensah WA; Miller WA; Mosi L; Wilson MD
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31234337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
    Adusumilli S; Haydel SE
    BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buruli ulcer (Mycobacterium ulcerans infection).
    Walsh DS; Portaels F; Meyers WM
    Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):969-78. PubMed ID: 18657836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.